Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy of Auvelity from entering the U.S. market until at least 2038.
In what one analyst called a “unique situation,” the company stopped dosing patients on the recommendation of trial monitors, ...
From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...
The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...
The investment firm is acquiring Mitsubishi Tanabe Pharma in a deal valued at $3.3 billion. Elsewhere, Bausch + Lomb hasn’t ...
The two biotechs, which have lost most of their share value following lucrative IPOs, are combining in a deal that leaves the ...
There is not a single member of AAM who has not raised concerns about the tariff situation,” said the CEO of the generic drug ...
The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...
The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies ...
Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback